We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Carnival Plc | LSE:CCL | London | Ordinary Share | GB0031215220 | ORD USD 1.66 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.00 | 0.09% | 1,083.50 | 1,083.00 | 1,084.00 | 1,086.50 | 1,070.00 | 1,072.00 | 23,462 | 10:12:14 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Water Trans Of Passenger,nec | 21.59B | -74M | -0.0566 | -191.61 | 14.17B |
From Apr 2022 to Apr 2024
By Denny Jacob
International stocks trading in New York closed higher on Wednesday.
The S&P/BNY Mellon index of American depositary receipts ticked up 1.5% to 142.96. The European index edged 1.6% higher to 138.82. The Asian index climbed 1.3% to 164.88. The Latin American index rose 1.2% to 181.30, while the emerging-markets index gained 1.6% to 276.38.
AstraZeneca PLC was among those whose ADRs traded actively.
The pharmaceutical company edged up 0.3% after it said imfinzi has been approved in the European Union for biliary tract cancer, while lynparza in combination with abiraterone and prednisone or prednisolone has been approved in the EU for prostate cancer.
Carnival PLC gained 4.4% after it narrowed its loss in the fourth quarter and said it saw bookings accelerate after it further relaxed Covid-19 protocols early in the quarter with momentum ongoing into December.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 21, 2022 18:22 ET (23:22 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Carnival Chart |
1 Month Carnival Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
